Tiziana Life Sciences LTD
Clinical-stage biopharmaceutical company developing alternative routes of immunotherapy for neuroinflammatory and neurodegenerative diseases. Core development focuses on fully human monoclonal antibodies delivered via non-invasive routes (intranasal, oral) alongside small-molecule oncology assets. Operates with academic clinical collaborators and pursues IND filings, expanded access programs and patent protection.
Industries
Nr. of Employees
small (1-50)
Tiziana Life Sciences LTD
14/15 Conduit Street, London W1S 2XJ, United Kingdom
Patents
Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US-11975111-B2
View DetailsDactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US-10973773-B2
View DetailsFormulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
US-10758541-B2
View Details
Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US-11975111-B2
View DetailsDactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
US-10973773-B2
View DetailsFormulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
US-10758541-B2
View DetailsProducts
Foralumab
A fully human anti-CD3 monoclonal antibody under clinical development for intranasal, oral and subcutaneous administration to induce regulatory T cells and reduce CNS inflammation.
Anti-IL-6R monoclonal antibody (TZLS-501)
A fully human monoclonal antibody targeting the interleukin-6 receptor intended to modulate IL-6-driven inflammation, evaluated for pulmonary and systemic inflammatory conditions.
Milciclib
Orally administered small-molecule multi-kinase inhibitor with clinical data from Phase 1–2 studies in solid tumors and thymic cancer; being evaluated in additional oncology indications and combinations.
Foralumab
A fully human anti-CD3 monoclonal antibody under clinical development for intranasal, oral and subcutaneous administration to induce regulatory T cells and reduce CNS inflammation.
Anti-IL-6R monoclonal antibody (TZLS-501)
A fully human monoclonal antibody targeting the interleukin-6 receptor intended to modulate IL-6-driven inflammation, evaluated for pulmonary and systemic inflammatory conditions.
Milciclib
Orally administered small-molecule multi-kinase inhibitor with clinical data from Phase 1–2 studies in solid tumors and thymic cancer; being evaluated in additional oncology indications and combinations.
Services
Design and conduct of clinical studies for nasal administration of biologics, including dose-ranging, imaging and immuno-biomarker endpoints.
Assessment and provisioning of investigational drugs to individual patients outside clinical trials following regulatory and ethical requirements.
Partnerships for product development and clinical supply to support IND submissions and study execution, including coordination with contract manufacturers.
Design and conduct of clinical studies for nasal administration of biologics, including dose-ranging, imaging and immuno-biomarker endpoints.
Assessment and provisioning of investigational drugs to individual patients outside clinical trials following regulatory and ethical requirements.
Partnerships for product development and clinical supply to support IND submissions and study execution, including coordination with contract manufacturers.
Expertise Areas
- Intranasal and mucosal immunotherapy
- Monoclonal antibody development and translational immunology
- Clinical trial management (Phase 1–2) and safety monitoring
- Neuroinflammation and CNS therapeutics
Key Technologies
- Intranasal drug delivery
- Enteric-coated oral formulations
- Fully human monoclonal antibodies
- TSPO-PET imaging
News & Updates
FDA permitted expansion of an intermediate-size expanded access program for intranasal anti-CD3 in non-active SPMS from 10 to 30 patients.
National Institute on Aging awarded grant funding to an academic investigator to study nasal anti-CD3 in Alzheimer’s disease.
Results reporting reduced microglial activation (TSPO-PET), induced regulatory immunity and stabilization of clinical progression in non-active SPMS patients treated with intranasal anti-CD3.
Dosing of first patient in a Phase 2a intranasal anti-CD3 study for MSA.
Six-month clinical data from expanded access non-active SPMS patients showed stabilization or improvement across measures including MFIS, EDSS, Timed 25-Foot Walk, pyramidal scores and NeuroQoL Fatigue.
Publication reporting PET imaging and immunologic analysis following nasal anti-CD3 treatment in a moderate Alzheimer’s patient.
FDA permitted expansion of an intermediate-size expanded access program for intranasal anti-CD3 in non-active SPMS from 10 to 30 patients.
National Institute on Aging awarded grant funding to an academic investigator to study nasal anti-CD3 in Alzheimer’s disease.
Results reporting reduced microglial activation (TSPO-PET), induced regulatory immunity and stabilization of clinical progression in non-active SPMS patients treated with intranasal anti-CD3.
Dosing of first patient in a Phase 2a intranasal anti-CD3 study for MSA.
Six-month clinical data from expanded access non-active SPMS patients showed stabilization or improvement across measures including MFIS, EDSS, Timed 25-Foot Walk, pyramidal scores and NeuroQoL Fatigue.
Publication reporting PET imaging and immunologic analysis following nasal anti-CD3 treatment in a moderate Alzheimer’s patient.